Asia Pacific Skin Cancer Diagnostics Market Size, Share & Trends Analysis Report By Type (Non-Melanoma and Melanoma), By Test Type (Skin Biopsy, Imaging Tests, Dermatoscopy, Lymph Node Biopsy, and Others), By End-use, By Country and Growth Forecast, 2024 - 2031

The Asia Pacific Skin Cancer Diagnostics Market is projected to witness market growth of 5.9% CAGR during the forecast period (2024-2031).

The China market dominated the Asia Pacific Skin Cancer Diagnostics Market by Country in 2023, and is forecast to continue being a dominant market till 2031; thereby, achieving a market value of $851.6 million by 2031. The Japan market is registering a CAGR of 5.4% during (2024 - 2031). Additionally, The India market would showcase a CAGR of 6.7% during (2024 - 2031).



The skin cancer diagnostics market is experiencing substantial growth due to the increasing cost of healthcare, which is indicative of the broader patterns in global health investment. According to the World Health Organization (WHO), global healthcare spending reached $8.3 trillion in 2020, accounting for approximately 10% of global GDP.

Moreover, Various factors fuel this upward trajectory in healthcare spending, including aging populations, advances in medical technology, and increased awareness and diagnosis of health conditions, including skin cancer.

Many countries within the Asia Pacific region are undergoing significant advancements in healthcare infrastructure. This includes the establishment of new hospitals, clinics, and diagnostic facilities. Improved access to these facilities fosters a more proactive approach to skin cancer screening and diagnosis. China has experienced a significant rise in skin cancer incidence, partly due to the rapid development of healthcare infrastructure.

List of Key Companies Profiled

• Castle Biosciences, Inc.
• Bausch Health Companies, Inc. (DermTech, Inc.)
• Canfield Scientific, Inc.
• DermaSensor, Inc.
• F.Hoffmann-La Roche Ltd.
• NeoGenomics, Inc.
• Quest Diagnostics Incorporated.
• Digital Diagnostics, Inc. (3Derm Systems, Inc.)
• FotoFinder Systems GmbH
• Veriskin Inc

Market Report Segmentation

By Type

• Non-Melanoma
• Melanoma

By Test Type

• Skin Biopsy
• Imaging Tests
• Dermatoscopy
• Lymph Node Biopsy
• Others

By End-use

• Hospital & Clinics
• Laboratories
• Others

By Country

• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific